Market capitalization | DKK9.95b |
Enterprise Value | DKK9.59b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 42.86 |
P/S ratio (TTM) P/S ratio | 44.45 |
P/B ratio (TTM) P/B ratio | 21.45 |
Revenue (TTM) Revenue | DKK223.82m |
EBIT (operating result TTM) EBIT | DKK-59.07m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
2 Analysts have issued a Gubra A/S forecast:
2 Analysts have issued a Gubra A/S forecast:
Jun '24 |
+/-
%
|
||
Revenue | 224 224 |
-
|
|
Gross Profit | 131 131 |
-
|
|
EBITDA | -49 -49 |
-
|
EBIT (Operating Income) EBIT | -59 -59 |
-
|
Net Profit | -47 -47 |
-
|
In millions DKK.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Gubra ApS operates as biotechnology company. It engages in the business of pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. The company operates through two business segments: CRO Services and Discovery & Partnerships. The CRO Services segment provides specialized pre-clinical contract research and development services for the pharmaceutical and biotechnology industry. The Discovery & Partnerships segment involves in discovery, design and development of peptide-based drug candidates with the aim of entering partnerships with pharmaceutical or biotechnology companies. Gubra was founded by Jacob Jelsing and Niels Vrang in 2008 and is headquartered in Horsholm, Denmark.
Head office | Denmark |
CEO | Henrik Blou |
Employees | 219 |
Founded | 2008 |
Website | www.gubra.dk |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.